GC
PACB icon

Guggenheim Capital’s Pacific Biosciences PACB Stock Holding History

Guggenheim Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,517
Closed -$54.9K – 1643
2025
Q1 		$54.9K Sell
46,517
-7,943
-15% -$12.2K ﹤0.01% 1625
2024
Q4 		$99.7K Sell
54,460
-17,703
-25% -$34.6K ﹤0.01% 1655
2024
Q3 		$123K Sell
72,163
-117,661
-62% -$193K ﹤0.01% 1818
2024
Q2 		$260K Sell
189,824
-37,702
-17% -$76.1K ﹤0.01% 1689
2024
Q1 		$853K Buy
227,526
+32,149
+16% +$188K 0.01% 1262
2023
Q4 		$1.92M Buy
195,377
+43,021
+28% +$352K 0.01% 863
2023
Q3 		$1.27M Sell
152,356
-75,735
-33% -$866K 0.01% 993
2023
Q2 		$3.03M Sell
228,091
-35,293
-13% -$429K 0.02% 695
2023
Q1 		$3.05M Sell
263,384
-17,912
-6% -$178K 0.03% 706
2022
Q4 		$2.3M Sell
281,296
-35,551
-11% -$306K 0.02% 804
2022
Q3 		$1.84M Sell
316,847
-7,529
-2% -$43.2K 0.02% 874
2022
Q2 		$1.43M Sell
324,376
-125,732
-28% -$764K 0.01% 1051
2022
Q1 		$4.1M Buy
450,108
+31,330
+7% +$361K 0.02% 726
2021
Q4 		$8.57M Buy
418,778
+81,136
+24% +$1.96M 0.04% 488
2021
Q3 		$8.63M Buy
337,642
+331,309
+5,231% +$9.82M 0.05% 438
2021
Q2 		$221K Buy
+6,333
New +$184K ﹤0.01% 2114
2019
Q4 		– Sell
-14,080
Closed -$73K – 2140
2019
Q3 		$73K Sell
14,080
-17,943
-56% -$100K ﹤0.01% 2074
2019
Q2 		$194K Buy
32,023
+127
+0.4% +$891 ﹤0.01% 2037
2019
Q1 		$231K Buy
+31,896
New +$231K ﹤0.01% 2013

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Guggenheim Capital's PACB Position: Q2 2025 in Review

Guggenheim Capital sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 46,517 shares — an estimated $54.9K sold.

Guggenheim Capital first reported a position in PACB in Q1 2019 and held it in 19 quarters. The position peaked at $8.63M in Q3 2021. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

  • Guggenheim Capital reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
  • Guggenheim Capital sold 46,517 Pacific Biosciences shares in Q2 2025, an estimated $54.9K.
  • Guggenheim Capital first reported a position in Pacific Biosciences in Q1 2019 and held it in 19 quarters.
  • Guggenheim Capital's Pacific Biosciences position peaked at $8.63M in Q3 2021.
  • 207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on Guggenheim Capital's 13F filing for Q2 2025, filed 13 Aug 2025.